Article3 Biotech2019
Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine.
Article in 3 Biotech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.Seminars in arthritis and rheumatism · 2021Pooled it
- FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.Clinical drug investigation · 2022Trial
- Article
- Boosting Antiviral Defenses: stat3 Inhibition Enhances Type I Interferon Response to Respiratory Syncytial Virus by Silencing KAP1.Current molecular medicine · 2026Article
- Phosphorylation Modifications and Their Role in Viral Pneumonia: Mechanisms and Therapeutic Implications.Infection and drug resistance · 2025Review
- Review
- Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology.Frontiers in pharmacology · 2023Article
- Article
- COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.Internal and emergency medicine · 2021Review
- Colchicine as a possible therapeutic option in COVID-19 infection.Clinical rheumatology · 2020Article
- The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.Journal of autoimmunity · 2020Review
- Treatments for COVID-19: emerging drugs against the coronavirus.Acta bio-medica : Atenei Parmensis · 2020Review
- Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19.Reumatologia · 2020Article
- Colchicine in COVID-19: an Old Drug, New Use.Current pharmacology reports · 2020Article
- Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.Reumatologia clinicaReview
- Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.Reumatologia clinicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigated the role of colchicine in the treatment of RSV infection. Treatment of BEAS-2B cells following RSV infection with colchicine caused a significant decrease in the number of viral plaques. In RSV-infected BEAS-2B cells' treatment with colchicine leads to a significant up-regulation of both IFN-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.